Navigation Links
Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008
Date:4/30/2009

Newly Approved Simponi is Expected to Achieve Strong Uptake in this Niche Market, According to a New Report from Decision Resources

WALTHAM, Mass., April 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the availability of Amgen/Wyeth/Takeda's Enbrel, Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade, and Abbott/Eisai's Humira has driven dramatic growth in the spondyloarthropathy (SpA) market, which reached nearly $2 billion in 2008 in the United States, France, Germany, Italy, Spain and United Kingdom. These agents have revolutionized the treatment of niche immune diseases known as the seronegative SpAs - ankylosing spondylitis, psoriatic arthritis, and reactive arthritis - and ushered in a period of strong sales growth in these markets.

The new Spectrum report entitled Strategic Overview of Spondyloarthropathies: Tapping the Market Opportunity of Niche Immune Diseases finds that the need for efficacious therapies to treat SpAs resulted in strong adoption of TNF-alpha inhibitors and, in turn, has proven to be a source of additional sales for blockbuster agents such as Enbrel, Remicade and Humira. In addition, physicians' familiarity with TNF-alpha inhibitors is expected to aid in the uptake of the newest agent in this drug class, Centocor/Schering-Plough/Janssen/Mitsubishi Tanabe's Simponi, which was approved in late April by the Food and Drug Administration (FDA) for the treatment of psoriatic arthritis and ankylosing spondylitis.

"Simponi's advantages over existing TNF-alpha inhibitors are appealing to rheumatologists, and we forecast strong adoption for this agent," said Decision Resources Analyst Jennifer Moniz Carpenter, M.B.A. "However the success of the TNF-alpha inhibitors has reduced the level of perceived need in these markets, and in order to be successful in this space, other companies developing agents for SpAs - including Bristol-Myers Squibb, Novartis and Celgene - will need to fully understand the dynamics and remaining needs of the individual indications that it comprises."

According to the report, the SpA market will continue to grow over the next five to ten years, although the sales picture across the three diseases will vary widely as the reactive arthritis drug sector is markedly different than the sectors for the other two diseases. While the combined market in 2008 for ankylosing spondylitis and psoriatic arthritis was approximately $1.8 billion, the reactive arthritis drug market in that year was only $3 million, and TNF-alpha inhibitors have not been widely incorporated into medical practice for this exceedingly rare disease.

About Spectrum's Strategic Overviews

Spectrum's Strategic Overviews are comprehensive examinations of dynamic biopharmaceutical markets and industry issues. Primary research, data analysis, thought-leader consultation and the expertise of the industry-savvy Spectrum staff drive reports that offer breadth of coverage along with depth of strategic insight.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                              Decision Resources, Inc.
    Christopher Comfort                             Elizabeth Marshall
    781-296-2597                                    781-296-2563
    ccomfort@dresources.com                         emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Adoption of Consumer-Driven Health Plans Accelerated by Recession
2. Siemens Enhances Knowledge-Driven Solutions to Support Provider Quality of Care Initiatives
3. Leader in Health Plan Cost Containment Cites Three Economy-Driven Reasons Why Self-Insured Health Plans Should Brace for Claim Increases and Fund Reserves Accordingly
4. Brain Fitness Industry Growth Driven By Science
5. Star-Driven Benefit Event to Help Provide Music Therapy to Sick Children
6. Parents and Advocates Label Todays Vaccine Court Rulings Insincere and Politically Driven, Says National Autism Association
7. HealthCentral Acquires Wellsphere Creating the Largest Organically Driven Online Health and Wellness Communities
8. Onvia Fills Critical Information Gap with Launch of its Economic Stimulus Toolkit, Enabling Businesses to Understand, Prepare for and Capitalize on Pending Stimulus-Driven Opportunities
9. MEMOTEXT Collaborating with Johns Hopkins University To Evaluate Technology-Driven Adherence Programs
10. Risk takers, drug abusers driven by decreased ability to process dopamine
11. AutismActionPlan.org Launches Doctor-Driven Biomedical Autism Treatment Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... OR (PRWEB) , ... March 23, 2017 , ... Sharon ... Water, Global Climate Change and Your Health on VoiceAmerica, recently talked on her program ... she also used the occasion to remind listeners of an important distinction. World Water ...
(Date:3/23/2017)... ... 23, 2017 , ... Corra Group is now offering exclusively ... Verisys through its FACIS and other services maintains the largest healthcare database ... are delighted to be able to offer these various products to our healthcare ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... and the New MEDDEV 2.7/1 Rev. 4 Guidance, **An FDAnews Webinar**, April ... , How will the new EU MDR language change the way manufacturers ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... “Wounded Woman ... “Wounded Woman Be Ye Healed-Passing On A Legacy” is the creation of published author, ... founder of Comfortbearers grief ministry. She has been happily married to her husband, ...
(Date:3/23/2017)... ... ... and strong explanation of the God’s love. “More Corruption” is the creation of published author, ... write a book about Him. , She says, “I’m fed up with mortals misjudging me ... God. They have not walked in my shoes and I know they never could for ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... YORK , March 23, 2017 ... sample preparation market is expected to reach USD 7.2 billion ... of 7.1%. Sample preparation is a procedure in which a ... crucial step in most analytical procedures since the methods are ... preparation is one of the most shared procedures in the ...
(Date:3/23/2017)... March 23, 2017  Drug diversion is a ... and deadly overdoses. A new oral fluid monitoring ... www.cordantsolutions.com , reports more detailed and actionable information ... potentially improve therapy adherence, patient safety, and help ... Comprehensive Oral fluid Rx Evaluation (CORE) system is ...
(Date:3/23/2017)... March 23, 2017  The goal of the ... identify and track prescription drugs as they are distributed ... response to requirements from US FDA to better protect ... dangerous medicines. Blockchain startup Chronicled, which ... chips and blockchain technology and recently raised $6.25M, and ...
Breaking Medicine Technology: